Pro-doping Enhanced Games to debut in Las Vegas with Trump Jr backing
The inaugural Enhanced Games will take place 21–24 May 2026 at Resorts World on the Las Vegas Strip. Over four days, competitors will race, lift and swim with full access to drugs and therapies banned in virtually every other elite athletic setting.
Related: On your marks, get set, dope! Welcome to the Enhanced Games – the sporting event no one wants | Marina Hyde
Billed as a revolution in sport and science, the event aims to embrace what organizers call 'superhumanity' – a future where pharmaceutical and technological enhancement is normalized in elite competition. But while promoters cast it as a bold break from the past, critics are already raising alarms about safety, fairness and the fundamental integrity of sport.
'We are creating a new category of human excellence,' the Enhanced Games' promotional materials declare. 'A world where performance-enhancing drugs are used safely, openly, and under medical supervision.'
The pitch is simple but radical: rather than penalize athletes for using banned substances, normalize and study their use in a medically supervised environment. Under the Enhanced model, athletes can either compete naturally, follow independent enhancement protocols, or participate in a clinical trial using FDA-approved drugs designated as 'Investigational Medicinal Products'.
The event's founder, the London-based Australian entrepreneur Aron D'Souza, argues that current anti-doping policies are outdated and hypocritical. 'The Enhanced Games is renovating the Olympic model for the 21st century,' he said. 'In the era of accelerating technological and scientific change, the world needs a sporting event that embraces the future – particularly advances in medical science.'
Organizers promise extensive medical screening, individualized health profiling and oversight by independent scientific and ethics boards. But athletes will not be subject to traditional anti-doping tests. Instead, they must disclose what substances they're using – a model that some critics warn resembles 'don't ask, don't tell' for doping in sport.
The first Games will be held at Resorts World in Las Vegas and feature sprinting, swimming and weightlifting. Prize money is substantial: up to $500,000 per event, including a $1m bonus for breaking the 100m sprint or 50m freestyle world records.
That may not be a theoretical reward. In February, Greek-Bulgarian swimmer Kristian Gkolomeev recorded a time of 20.89sec in the 50m freestyle – 0.02sec faster than the official world record, which has stood since 2009 – reportedly while following an enhancement protocol for the first time. The swim, held at a certified pool under Olympic-level oversight, was filmed for a forthcoming promotional documentary.
Yet even this demonstration comes with caveats. Gkolomeev wore a full-body polyurethane suit not approved by Fina, swimming's international governing body. Organizers claim the suit was commercially available and not decisive in the performance – but its inclusion underscores the ethical gray areas the Enhanced Games are poised to explore.
More fundamentally, many observers are uneasy with the concept itself.
'As we have seen through history, performance-enhancing drugs have taken a terrible physical and mental toll on many athletes. Some have died,' the World Anti-Doping Agency said in a statement. 'Clearly this event would jeopardize [athletes' health and well-being] by promoting the abuse of powerful substances and methods that should only be prescribed, if at all, for specific therapeutic needs.'
Travis Tygart, CEO of the US Anti-Doping Agency, was even more blunt. 'It's a dangerous clown show, not real sport,' he said.
Related: 'Imagine if a 60-year-old broke Usain Bolt's record': the story behind the Enhanced Games, the Olympics where everyone dopes
The Enhanced Games are also attracting attention, and controversy, due to the event's supporters. The latest funding round, reportedly in the millions, includes investment from 1789 Capital, a firm led by Donald Trump Jr, Omeed Malik and Chris Buskirk. Other co-leads include Apeiron Investment Group and Karatage, a hedge fund with stakes in cryptocurrency and AI ventures. A video announcing the funding suggests Donald Trump's endorsement.
D'Souza described the involvement of Trump-aligned investors as a natural fit. 'I've had the great fortune of working alongside many members of the administration and other prominent figures of the Trump movement over the years,' he said in February. 'To know that some of the most significant figures in American social and political life support the Enhanced Games is more important to us than any investment.'
Peter Thiel, the tech billionaire known for his libertarian politics and backing of controversial biotech ventures, is also listed as a major investor and 'close advisor', according to D'Souza.
The participation of such figures has drawn further scrutiny from critics who view the Enhanced Games as not only a break from the Olympic model, but a calculated provocation – a challenge to elite sporting institutions, anti-doping agencies and what D'Souza has called the 'anti-science' bent of legacy sports governance.
Organizers maintain they are not trying to overwrite Olympic records or discredit traditional sport. Instead, they frame the Enhanced Games as a parallel category, akin to the professionalization of sport in the 20th century. The goal, they argue, is to explore the boundaries of human potential while provoking a broader cultural conversation.
It's an ambitious vision – and a high-stakes gamble.
Athletes from around the world are being recruited, including some who felt alienated by anti-doping regimes. Former swimming world champion James Magnussen is among them, though the Australian's recent enhanced attempts fell short of record times.
The organizers, now headquartered in New York, say they will not tolerate abuse of illicit substances. Drugs must be legally prescribed and athletes must be medically fit to compete. Still, enforcement appears to rely more on partnership than oversight – a feature, not a bug, according to the Enhanced team.
'There are always risks in elite sport,' reads one of the Games' internal FAQs. 'We believe the greater risk is pretending those risks don't exist.'
Whether the public buys into that logic remains to be seen. Organizers say they are in talks with major sponsors and streaming platforms, but have not confirmed any broadcast partners or marquee athletes beyond a handful of early adopters. If backlash builds – from federations, governments or regulators – it's unclear whether the model will survive its first test.
For now, though, the Enhanced Games are moving ahead, armed with a defiant slogan: Live Enhanced.
Whether the world embraces that vision or recoils from it may determine not just the future of one event, but the ethical limits of sport itself.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Who is leading MLB's MVP, Cy Young and Rookie of the Year races?
Yahoo Sports AM is our daily newsletter that keeps you up to date on all things sports. Sign up here to get it every weekday morning. 🚨 Headlines 🇺🇸 USOPC trans ban: The U.S. Olympic and Paralympic Committee has effectively barred transgender women from competing in women's sports, citing an "obligation to comply" with an executive order issued by President Donald Trump. ⚾️ Holliday gets record bonus: The Rockies gave No. 4 pick Ethan Holliday a $9 million signing bonus, the most ever given to a high schooler and the fourth-most among all draft picks in MLB history. 🏀 Ratings drop: The WNBA All-Star Game drew 2.2 million viewers, which is the second-most ever but still represents a 36% drop from last year (3.44M), when Caitlin Clark (who didn't participate this year) led her All-Star teammates against the U.S. Olympic team. 🏈 Hendrickson holds out: Bengals edge rusher Trey Hendrickson did not report to training camp amid a monthslong contract dispute. The four-time Pro Bowler called Cincinnati's latest offer "atrociously low." 🏈 UFL teams to relocate: The UFL's entire USFL division (Birmingham Stallions, Houston Roughnecks, Memphis Showboats, Michigan Panthers) will reportedly be relocated for the 2026 season. ⚾️ MLB awards watch With MLB's second half underway, and just over two months left in the regular season, let's take stock of the three major awards races. American League MVP: With all due respect to the greatest offensive season by a catcher in MLB history and the Cy Young frontrunner, this one's a slam dunk at the moment. Aaron Judge (NYY): The Yankees captain is having the best season of his career in the midst of one of the greatest four-year runs in league history. He's on pace for 12.3 WAR, per FanGraphs, which would be the best since Barry Bonds in the early aughts. Remove Bonds, and it's the best since Babe Ruth and Lou Gehrig in 1927. Cal Raleigh (SEA): The Mariners backstop is on track to become the first catcher with a 50-homer season, and Judge and Shohei Ohtani are the only players in baseball with a better OPS. Just a remarkable year from Big Dumper. Tarik Skubal (DET): With no other hitter clearly in third place, this goes to the league's best pitcher for two years running. Cy Young: Skubal is vying to become the first back-to-back AL Cy Young winner since Pedro Martínez in 1999-2000, but his competition in Boston isn't that far behind. Skubal (DET): Detroit's ace leads all qualified MLB starters in both strikeout and walk rate, which is outrageous. He also has the best WHIP (0.81) and is tied for the best ERA (2.19) in the AL. Garrett Crochet (BOS): The hard-throwing southpaw leads the majors in strikeouts (165) and is tied with Skubal for the AL's best ERA. And to think he only became a starter last year. Hunter Brown (HOU): While his numbers are still excellent (2.57 ERA, 0.99 WHIP), a couple so-so starts in July have opened the door for guys like Jacob deGrom (2.28 ERA, 0.90 WHIP) and Max Fried (2.43 ERA, 1.01 WHIP) to take his spot. Rookie of the Year: The Athletics might not have a home city or a major league ballpark, but they do have the league's two best rookies. Jacob Wilson (A's): The first rookie shortstop ever voted by fans to start the All-Star Game has the fifth-best average in the majors (.315). Nick Kurtz (A's): He's the only AL rookie with more homers or a higher OPS than Wilson, and with 29 fewer games played this race could tighten considerably. Carlos Narváez (BOS): The Red Sox backstop has the third-best OPS among all AL catchers (.774). National League MVP: At some point, Shohei Ohtani will cede the throne of the greatest player on the planet. We are nowhere near that point as he barrels toward his fourth MVP in five years. Ohtani (LAD): The same guy who leads the NL in HR (36), runs (95) and OPS (.993) also has a 1.50 ERA through six starts since returning from elbow surgery. Pete Crow-Armstrong (CHC): The Cubs' youngster is arguably the best outfielder in the majors, to say nothing of his 26 HR and 28 SB, both top five in the NL. Add it up and he trails only Judge for the MLB lead in WAR. Juan Soto (NYM): All-Star snub and cold start aside, the Mets' $765 million man has looked like himself — aka a top five player — for at least the last two months. Cy Young: As with the AL, this is a two-man race at the moment. Zack Wheeler (PHI): On the one hand, you have Philly's two-time runner-up who leads the league in WHIP (0.88) and strikeouts (164) and is third in ERA (2.39). Paul Skenes (PIT): On the other is Pittsburgh's phenom, who boasts a league-best 1.91 ERA and a stellar 0.91 WHIP that trails only Wheeler's. Good thing we've still got two months left to sort this out. Logan Webb (SF): The Giants' ace is leading the NL in innings for the third straight year, and could nab his third straight top-six Cy Young finish. Rookie of the Year: Who do you choose: the solid player who's been there all season or the lightning rod with just six starts under his belt? Drake Baldwin (ATL): The Braves' backstop has an .837 OPS and 11 HR (both second among NL rookies) to go along with above-average defense behind the dish. Jacob Misiorowski (MIL): The rookie sensation boasts a 2.45 ERA and 0.92 WHIP, which earned him a controversial All-Star selection after just five starts. Hyeseong Kim (LAD): The 26-year-old Korean is batting a scorching .317 through 53 games for the reigning champs. 🎧 Listen: What to watch for post All-Star break (Baseball Bar-B-Cast, Yahoo Sports) 📸 Through the lens Washington, D.C. — A day after winning her doubles match, 45-year-old Venus Williams stunned world No. 35 Peyton Stearns with a straight-sets victory at the DC Open — her first tour-level singles match in over a year and first win since 2023. Unreal. Turn back the clock: Williams is the oldest player to win a tour-level singles match since 2004, when 47-year-old Martina Navratilova won in the first round at Wimbledon. Geneva, Switzerland — Defending champion England is headed back to the Women's Euro final after their 2-1 comeback victory over Italy. They get the winner of Germany-Spain on Sunday. Historic strike: Chloe Kelly's 119th-minute game-winner, a rebound off her own blocked penalty kick, was the latest game-winning goal in Women's Euro history. Mont Ventoux, France — Tadej Pogačar made history on Tuesday in his pursuit of a fourth Tour de France victory, climbing the iconic Mont Ventoux in just 54:51, a full minute faster than the previous record. France gets on the board: Valentin Paret-Peintre won Stage 16 to give the host nation its first stage win of this year's race. Pogačar still holds the overall lead by 4 minutes, 15 seconds over Jonas Vingegaard. 🏀 Yang Hansen has arrived The Trail Blazers shocked the NBA world last month when they drafted Chinese center Yang Hansen with the No. 16 pick. How surprising was the pick? When Yang's name was called, he was sitting in the stands with fans rather than in the green room with his fellow draftees because he hadn't received an invitation. Sin City sensation: Despite being a relative unknown in America, the 7-foot-1 Yang is already a phenomenon in his native country. That was apparent this month in Las Vegas, where he was one of the biggest stars of Summer League, writes Ben Golliver of the Washington Post: Thousands of Chinese and Chinese American fans traveled to Sin City to watch Yang play … Tencent, a Chinese media company, dispatched a documentary crew to follow him … and more than a dozen reporters from China covered his games. Back in China, 5.2 million people watched Tencent's free broadcast of the Blazers' exhibition against the Grizzlies, according to an NBA official, dwarfing the 1.1 million Americans who watched No. 1 pick Cooper Flagg's debut for the Mavericks on ESPN. On Tencent's paywalled service, one of Yang's games drew 3.4 million viewers — 16 times the service's average. And on China Central Television, Yang's summer league games garnered larger average audiences than the national broadcast network's telecasts of this year's NBA playoffs. Next in line: Yang is the third Chinese player to be drafted in the first round, joining Yao Ming (No. 1 in 2002) and Yi Jianlian (No. 6 in 2007). His favorite player is Nikola Jokić and he flashed Jokić-like vision in Vegas, where Yang had a higher assist rate than any of the 15 players picked ahead of him. 🏈 Coming soon: College football! The 2025 college football season kicks off exactly one month from today. Here are some stories to get you up to speed, courtesy of Yahoo Sports' Nick Bromberg. Familiar faces, new places: 10 biggest QB transfers to know Miami's Carson Beck (from Georgia), UCLA's Nico Iamaleava (Tennessee) and Oklahoma's John Mateer (Washington State) headline the list of high-profile signal callers who will be donning new jerseys this fall. Coaching carousel: Here are all the new head coaches Just six power conference schools (UNC, Wake Forest, Stanford, Purdue, UCF, West Virginia) hired new head coaches this offseason, but there was plenty of movement elsewhere. More from Yahoo Sports: CFP expansion: The latest buzz Betting: Win totals for every team QB battles: Competitions to watch Looking ahead: The season begins on August 23, with Iowa State vs. Kansas State (in Dublin, Ireland) headlining Week 0. 📺 Watchlist: Wednesday, July 23 ⚽️ MLS All-Star Game | 9pm ET, Prime/Apple The best players from North America's top two leagues go head-to-head, with the MLS All-Stars (led by Lionel Messi) hosting the Liga MX All-Stars in Austin. ⚽️ Germany vs. Spain | 3pm, Fox The second Women's Euro semifinal pits eight-time tournament champion Germany against reigning World Cup champion Spain. The winner gets England in Sunday's final. More to watch: ⚾️ MLB: Red Sox at Phillies (7pm, ESPN); Yankees at Blue Jays (7pm, Prime) 🚴 Tour de France: Stage 17 (7:35am, Peacock) … Riders travel 100 miles from Bollène to Valence in southeastern France. 🏀 WNBA: Dream at Mercury (10pm, CBSSN) … Atlanta (13-10) visits Phoenix (15-7) in a battle of likely playoff teams. Today's full slate → 🍿 Movie trivia "Happy Gilmore 2," the sequel to the popular 1996 comedy, premiered in NYC on Tuesday and hits Netflix on Friday. Question: What other golf movie beat "Happy Gilmore" at the 1996 box office? Answer at the bottom. 🏈 28 days of fantasy For many of us, Yahoo Fantasy is the first place we had a football league. For others, it's the tried-and-true place we go every fantasy football season, creating a ritual that we share with friends and family each and every Sunday. To celebrate our 28th year of delivering fantasy football, we're dropping 28 BIG NEW features over 28 straight days starting August 4. More ways to play. More ways to draft. More ways to win. Learn more. Trivia answer: "Tin Cup" We hope you enjoyed this edition of Yahoo Sports AM, our daily newsletter that keeps you up to date on all things sports. Sign up here to get it delivered to your inbox every weekday morning.


Business Wire
20 minutes ago
- Business Wire
Hyperfine Begins Commercial Launch of Optive AI™ Software, Bringing Substantially Improved Image Quality to the Installed Base of Swoop® Systems
GUILFORD, Conn.--(BUSINESS WIRE)-- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced the commercial launch of the Optive AI™ software for existing Swoop® system customers. Optive AI™ software, which also powers the transformative image quality of the next-generation Swoop® system, is now commercially available to customers in the U.S. With over 650 scans under our belt on the previous software, with just a single scan in critical care today after installing Optive AI™ software on the Swoop® system, the difference is crystal clear. Share Optive AI™ software enhances each stage of the imaging process—from noise cancellation and image acquisition to reconstruction and post-processing. The result is brain images with greater clarity, uniformity, and sharper anatomical detail. The FDA cleared Optive AI™ software in late May 2025, and the software is also available for commercial use in Canada, Australia, and New Zealand, with additional international approvals expected later this year. Hyperfine has now begun rolling out the new software to hospitals and outpatient neurology offices in the U.S. with plans to bring this imaging software to all current customers in the coming weeks. Jennifer Villa Frabizzio, MD, Chief of Neuroradiology, Jefferson Abington Hospital, noted, 'With over 650 scans under our belt on the previous software, with just a single scan in critical care today after installing Optive AI™ software on the Swoop® system, the difference is crystal clear. FLAIR images, especially, show markedly improved resolution and are 40 seconds faster. Kudos to Hyperfine engineers for this large leap.' Chetan Shah, MD, Chair, Pediatric Radiology, Wolfson Children's Hospital, noted, 'This upgrade is a true game changer for MRI technology—an overnight leap in image quality that's rarely seen. Portable MRI can now extend beyond the ICU to serve ER patients and outpatients—a breakthrough in every sense.' Optive AI™ software is fully compatible with first-generation Swoop® systems and requires no hardware modifications, enabling current users to immediately benefit from next-generation image quality. The new software supports a wide range of patient populations, as well as various clinical use cases in emergency, intensive care, and neurology office settings. 'We're thrilled to bring the power of Optive AI™ software to our current customers,' said Maria Sainz, President and CEO of Hyperfine. 'This is more than a software update—it's a milestone that reflects our commitment to sustained innovation, improved clinical performance, and driving the adoption of portable brain MRI across multiple sites of care. We are incredibly pleased with the feedback from the initial cases of patients scanned with the Optive AI™ software and look forward to broadening clinical utility with this high level of image quality for patients in different care settings inside and outside of the hospital.' For more information about the Swoop® system and Optive AI™ software, please visit About the Swoop® Portable MRI Systems The Swoop® Portable MR Imaging® Systems are U.S. Food and Drug Administration (FDA) cleared for brain imaging of patients of all ages. They are portable, ultra-low-field magnetic resonance imaging devices for producing images that display the internal structure of the head where full diagnostic examination is not clinically practical. When interpreted by a trained physician, these images provide information that can be useful in determining a diagnosis. About Hyperfine, Inc. Hyperfine, Inc. (Nasdaq: HYPR) is the groundbreaking health technology company that has redefined brain imaging with the Swoop® system—the first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system capable of providing imaging at multiple points of professional care. The mission of Hyperfine, Inc. is to revolutionize patient care globally through transformational, accessible, clinically relevant diagnostic imaging. Founded by Dr. Jonathan Rothberg in a technology-based incubator called 4Catalyzer, Hyperfine, Inc. scientists, engineers, and physicists developed the Swoop® system out of a passion for redefining brain imaging methodology and how clinicians can apply accessible diagnostic imaging to patient care. For more information, visit The Hyperfine logo, Swoop, and Portable MR Imaging are registered trademarks of Hyperfine, Inc. The Swoop logo, Optive AI logo, and Optive AI are trademarks of Hyperfine, Inc. Forward-Looking Statements This press release includes 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. Actual results of Hyperfine, Inc. (the 'Company') may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as 'expect,' 'estimate,' 'project,' 'budget,' 'forecast,' 'anticipate,' 'intend,' 'plan,' 'may,' 'will,' 'could,' 'should,' 'believes,' 'predicts,' 'potential,' 'continue,' and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company's goals and commercial plans, the benefits of the Company's products and services, and the Company's future performance and its ability to implement its strategy. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the Company's control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the success, cost and timing of the Company's product development and commercialization activities, including the degree that the Swoop® system is accepted and used by healthcare professionals; the impact of COVID-19 on the Company's business; the inability to maintain the listing of the Company's Class A common stock on the Nasdaq; the Company's inability to grow and manage growth profitably and retain its key employees; changes in applicable laws or regulations; the inability of the Company to raise financing in the future; the inability of the Company to obtain and maintain regulatory clearance or approval for its products, and any related restrictions and limitations of any cleared or approved product; the inability of the Company to identify, in-license or acquire additional technology; the inability of the Company to maintain its existing or future license, manufacturing, supply and distribution agreements and to obtain adequate supply of its products; the inability of the Company to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently marketing or developing; the size and growth potential of the markets for the Company's products and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company's products and services and reimbursement for medical procedures conducted using the Company's products and services; the Company's estimates regarding expenses, revenue, capital requirements and needs for additional financing; the Company's financial performance; and other risks and uncertainties indicated from time to time in Company's filings with the Securities and Exchange Commission, including those under 'Risk Factors' therein. The Company cautions readers that the foregoing list of factors is not exclusive and that readers should not place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.


CNN
2 hours ago
- CNN
FDA's artificial intelligence is supposed to revolutionize drug approvals. It's making up nonexistent studies.
To hear health officials in the Trump administration talk, artificial intelligence has arrived in Washington to fast-track new life-saving drugs to market, streamline work at the vast, multibillion-dollar health agencies, and be a key assistant in the quest to slash wasteful government spending without jeopardizing their work. 'The AI revolution has arrived,' Health and Human Services Secretary Robert F. Kennedy Jr. has declared at congressional hearings in the past few months. 'We are using this technology already at HHS to manage health care data, perfectly securely, and to increase the speed of drug approvals,' he told the House Energy and Commerce Committee in June. The enthusiasm — among some, at least — was palpable. Weeks earlier, the US Food and Drug Administration, the division of HHS that oversees vast portions of the American pharmaceutical and food system, had unveiled Elsa, an artificial intelligence tool intended to dramatically speed up drug and medical device approvals. Yet behind the scenes, the agency's slick AI project has been greeted with a shrug — or outright alarm. Six current and former FDA officials who spoke on the condition of anonymity to discuss sensitive internal work told CNN that Elsa can be useful for generating meeting notes and summaries, or email and communique templates. But it has also made up nonexistent studies, known as AI 'hallucinating,' or misrepresented research, according to three current FDA employees and documents seen by CNN. This makes it unreliable for their most critical work, the employees said. 'Anything that you don't have time to double-check is unreliable. It hallucinates confidently,' said one employee — a far cry from what has been publicly promised. 'AI is supposed to save our time, but I guarantee you that I waste a lot of extra time just due to the heightened vigilance that I have to have' to check for fake or misrepresented studies, a second FDA employee said. Currently, Elsa cannot help with review work , the lengthy assessment agency scientists undertake to determine whether drugs and devices are safe and effective, two FDA staffers said. That's because it cannot access many relevant documents, like industry submissions, to answer basic questions such as how many times a company may have filed for FDA approval, their related products on the market or other company-specific information. All this raises serious questions about the integrity of a tool that FDA Commissioner Dr. Marty Makary has boasted will transform the system for approving drugs and medical devices in the US, at a time when there is almost no federal oversight for assessing the use of AI in medicine. 'The agency is already using Elsa to accelerate clinical protocol reviews, shorten the time needed for scientific evaluations, and identify high-priority inspection targets,' the FDA said in a statement on its launch in June. But speaking to CNN at the FDA's White Oak headquarters this week, Makary says that right now, most of the agency's scientists are using Elsa for its 'organization abilities' like finding studies and summarizing meetings. The FDA's head of AI, Jeremy Walsh, admitted that Elsa can hallucinate nonexistent studies. 'Elsa is no different from lots of [large language models] and generative AI,' he told CNN. 'They could potentially hallucinate.' Walsh also said Elsa's shortcomings with responding to questions about industry information should change soon, as the FDA updates the program in the coming weeks to let users upload documents to their own libraries. Asked about mistakes Elsa is making , Makary noted that staff are not required to use the AI. 'I have not heard those specific concerns, but it's optional,' he said. 'They don't have to use Elsa if they don't find it to have value.' Challenged on how this makes the efficiency gains he has publicly touted when staff inside FDA have told CNN they must double-check its work, he said: 'You have to determine what is reliable information that [you] can make major decisions based on, and I think we do a great job of that.' The earliest iterations of Elsa were built from the backbone of an earlier AI model that the FDA had started to work on during the Biden administration, according to two sources familiar with the matter. The name was initially an acronym for Efficient Language System for Analysis and was among several pitches for names for the AI system, like 'RegulAItor.' Elsa eventually won out, though leadership ultimately decided against its longer title: A recent internal document seen by CNN says that now 'Elsa is just a name and is not an acronym.' Walsh and his team demonstrated the AI tool for CNN this week. The platform has a plain white interface with some brown accents. It welcomes the user with 'How can I help you?' above an entry field that says 'Ask Elsa anything,' much like other popular publicly used AI. The FDA has said that Elsa is designed to let regulators tap into secure internal documents, shortening reviews by quickly summarizing risky side effects and pulling in information about related products. During the demonstration, Elsa was asked to summarize the FDA's guidance on fatty liver disease and medicines that treat it. It pulled up the 10 papers from an internal FDA library that it said were the most relevant. When it was adopted in June, Makary boasted that Elsa's rollout had come 'ahead of schedule and under budget' after 'a very successful pilot program with FDA's scientific reviewers.' Walsh said those efforts came together in a matter of weeks. The agency leadership chose staff from across its various centers overseeing drugs, devices, food and animal medicines for a series of meetings in May. There, they gave feedback about what they needed from such a tool, potential challenges they saw and even some aesthetic choices, like Elsa's color palette and its name, according to an FDA employee who participated. Those who participated in the feedback meetings were dubbed Elsa 'champions' and sent to evangelize the platform in their various corners of the agency, with talking points and suggestions about how to demonstrate its use, according to two current FDA staff. Agency training on Elsa is voluntary, as is using the platform at all. Makary and Walsh told CNN that more than half of FDA staff have logged time in Elsa. But those who spoke to CNN said that the adoption has been weak in their areas of the agency — not many of their colleagues are using Elsa, or they are using it only on a very limited basis. Those who have used it say they have noticed serious problems. For example, it cannot reliably represent studies. If Elsa gives a one-paragraph summary of, say, 20 pages of research tied to a particular new drug, there is no way to know whether it misrepresents something or misses something that a human reviewer would have considered important, one FDA employee said. There is no way for Elsa to know what information from a lengthy study could be the most crucial for an expert, this employee believes. When Elsa is told it is incorrect — that a study it cites does not exist or that someone works at the FDA when they don't — it is usually 'apologetic,' one employee said. But in at least one instance shared with CNN — when that employee asked Elsa to generate something for a project — it insisted that research area was not in FDA's purview (it was). Employees who spoke to CNN have tested Elsa's knowledge by asking it questions like how many drugs of a certain class are authorized for children to use or how many drugs are approved with a certain label . In both cases, it returned wrong answers. One employee described Elsa miscounting the number of products with a particular label. When told it was wrong, the AI admitted that it made a mistake. 'But it still doesn't help you to answer the question,' that employee said. The algorithm then reminds users that it is only an AI assistant and they need to verify its work. Asked about errors, in addition to the hallucinations, Walsh said: 'Some of those responses don't surprise me at all. But what's important is … how we address those gaps in the capability' of Elsa and its users. Those include trainings and new features like the personal document libraries that will launch soon, he added. Walsh also said that a current feature of Elsa, where users can click over its summaries to see which parts of a document Elsa has cited, can act as a check to make sure it did not fabricate a study. However, this now applies only when Elsa is being used to pull internal documents. As of now, it cannot link to, for example, articles in a medical journal. And knowing whether those sources are, in fact, the most important is also up to the user and how they ask the questions, Walsh said. He also contended that the problem of Elsa's hallucinations can be mitigated by asking it more precise questions. Elsa is also improving, he insists. 'We're also seeing as the AI models get better, right, feedback gets better.' Talk of integrating artificial intelligence into US health agencies' work had been underway for some time before the second Trump administration jump-started efforts, but the speed with which Elsa came into use was unusual. Some experts would pinpoint the government's efforts to develop AI plans in earnest in 2018, when the Pentagon began evaluating its potential for national security. Part of that project was about looking into its use in health care too, said Dr. Hassan Tetteh, a thoracic surgeon and former US Navy captain who worked on the project in 2020. There were also early efforts from that Pentagon-led group to talk with international allies about AI standards and regulations, he added. In Europe, countries have worked together to stand up AI safeguards. In 2024, the European Union approved and implemented the AI Act, a law 'to protect fundamental rights, democracy, the rule of law' around risky AI use, including in health care, while promoting transformational AI models. These standards and protections do not exist in the US. A government working group formed during the Biden administration to look at establishing regulations on AI use, including in health care, was disbanded last year: It's mandate expired and was not renewed. Elsa arrived as Congress wrestled with how to approach laws on AI regulation. Although congressional committees have held hearings about AI risks like biased models and cybersecurity threats, Congress has passed no substantial legislation to regulate AI. In June, a bipartisan group of House members introduced legislation mostly focused on maintaining US dominance in the AI race; later that month, two senators introduced a bill trained on preventing American use of 'adversarial' AI from foreign governments, including China. Other efforts, such as a bill that would require testing and regulatory oversight for high-risk AI systems (much like the European standards), have stalled. An earlier version of the 'One Big Beautiful Bill,' President Donald Trump's expansive tax and spending bill, would have included Congress' first sweeping law on AI: a 10-year moratorium on the enforcement of state regulations of the technology. But the Senate struck the provision down. Trump, who has made AI development and investments a top priority in his second administration, has heralded a bright future for the technology. At an energy summit in Pennsylvania last week, he told attendees: 'We're here today because we believe that America's destiny is to dominate every industry and be the first in every technology, and that includes being the world's number one superpower in artificial intelligence.' Without federal regulations, it is hard to say what that superpower would look like. 'AI does a lot of stuff, but it's not magic,' said Dr. Jonathan Chen, an assistant professor of medicine at Stanford University who has studied the use of AI in clinical settings. It would be great if it could help experts sniff out data falsification or give rigorous analysis on patient safety, but 'those problems are much more nuanced' than what a machine can do, he said. 'It's really kind of the Wild West right now. The technology moves so fast, it's hard to even comprehend exactly what it is.'